ClinicalTrials.gg
CompletedNCT03400332Updated Feb 24, 2026Results posted

A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

A Phase 1/2 interventional study of BMS-986253 and Nivolumab in Cancer and Melanoma, sponsored by Bristol-Myers Squibb. Completed at 72 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-24.

Primary conditionMelanomaRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Melanoma
Why
  1. The study's listed conditions name Melanoma, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
281
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 111 studies in Melanoma by Bristol-Myers Squibb — 3 open to participants now, 9 under way, 3 of them phase 3. Melanoma · Bristol-Myers Squibb.

Enrollment
22nd of 75
281 · median 107
Started
2018
with 4 others
Phase 1/2
6 of 111
1 open now
Registered
80th of 111
by date

Among the 111 studies in Melanoma by Bristol-Myers Squibb, this one is the 22nd largest by enrollment of the 75 interventional ones that give a count, is one of 5 that started in 2018, is one of 6 in phase 1/2, and was the 80th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.

Browse Melanoma studies →

Open to participants now

3 of the 111 studies in Melanoma by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies in Melanoma by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to investigate experimental medication BMS-986253 in combination with Nivolumab or Nivolumab plus Ipilimumab in participants with advanced cancers.

03

Conditions studied

  • Cancer
  • Melanoma

Browse trials for

04

In context

Melanoma Reclassified

3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.

This study's enrollment of 281 is above the median of 40 across 2,652 interventional studies indexed under Melanoma.

Browse Melanoma studies →

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Compared within Melanoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histologic or cytologic confirmation of a solid tumor that is advanced (, recurrent and/or unresectable) with per v1.1
  • At least 1 lesion accessible for
  • Performance Status of 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Participants with as the only site of active disease (Participants with controlled brain metastases; however, will be allowed to enroll)
  • Participants with active, known or suspected disease
  • Participants with conditions requiring systemic treatment with either (> 10mg prednisone equivalents) or other medications within 14 days of study treatment administration
  • Participants with a known history of testing positive for (HIV) or known Acquired Immunodeficiency Syndrome (AIDS)
  • Cytotoxic agents, unless at least 4 weeks have elapsed from last dose of prior anti-cancer therapy and initiation of study therapy

Other protocol defined inclusion/exclusion criteria could apply

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
281 participants (actual)

Study arms

  • Experimental
    Part 1A: BMS-986253 + nivolumab

    Drug: BMS-986253 · Biological: Nivolumab

  • Experimental
    Part 1B: BMS-986253 + nivolumab

    Drug: BMS-986253 · Biological: Nivolumab

  • Experimental
    Part 1C: BMS-986253 + nivolumab + ipilimumab

    Drug: BMS-986253 · Biological: Nivolumab · Biological: Ipilimumab

  • Experimental
    Part 2A: BMS-986253 + nivolumab + ipilimumab

    Drug: BMS-986253 · Biological: Nivolumab · Biological: Ipilimumab

  • Placebo comparator
    Part 2B: Placebo + nivolumab + ipilimumab

    Biological: Nivolumab · Biological: Ipilimumab · Other: Placebo

Interventions

  • Specified dose on specified days

  • BiologicalNivolumab

    Specified dose on specified days

    Also known as: BMS-936558, Opdivo

  • BiologicalIpilimumab

    Specified dose on specified days

    Also known as: BMS-734016, YERVOY

  • OtherPlacebo

    Specified dose on specified days

07

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Adverse Events (AEs) - Part 1

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal. This endpoint was prespecified in the protocol to include only participants in Part 1.

    Time frame: From first dose up to 100 days after last dose (up to 65 months)

  2. Number of Participants Experiencing Serious Adverse Events (SAEs) - Part 1

    A serious adverse event is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is an important medical event. This endpoint was prespecified in the protocol to include only participants in Part 1.

    Time frame: From first dose up to 100 days after last dose (up to 65 months)

  3. Number of Participants Experiencing Dose Limiting Toxicities (DLTs) - Part 1

    Dose-Limiting Toxicities (DLTs) are effects of a treatment that are serious enough to prevent an increase in dose of that treatment, as advised by the Dose Review Team. DLTs will be defined based on the incidence, intensity, and duration of AEs that are possibly related to study treatment. DLTs will include gastrointestinal, hepatic, hematologic, dermatologic, and other AEs. This endpoint was prespecified in the protocol to include only participants in Part 1.

    Time frame: From first dose up to 100 days after last dose (up to 65 months)

  4. Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation - Part 1

    Number of participants with any grade adverse events (AEs) leading to discontinuation of study treatment. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. Toxicities will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. This endpoint was prespecified in the protocol to include only participants in Part 1.

    Time frame: From first dose up to 100 days after last dose (up to 65 months)

  5. Number of Participants Who Died - Part 1

    The number of participants who died due to any cause are summarized. This endpoint was prespecified in the protocol to include only participants in Part 1.

    Time frame: From first dose up to 100 days after last dose (up to 65 months)

  6. Most Frequently Reported Grade 3 and Grade 4 Laboratory Test Results - Part 1

    Laboratory results were graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Laboratory tests are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal. This endpoint was prespecified in the protocol to include only participants in Part 1.

    Time frame: From first dose up to 30 days after last dose (up to 63 months)

  7. Objective Response Rate (ORR) - Part 2

    Objective Response Rate per blinded independent central review (BICR) is the percentage of participants who have a confirmed complete or partial best overall response (BOR) among participants who have measurable disease at baseline. Complete Response (CR) is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to =\< 10 mm. Partial Response (PR) is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Baseline was defined as evaluations or events that occur before the date and time of the first dose of study treatment or evaluations on the same date and time of the first dose of study treatment were also considered as baseline evaluations. This endpoint was prespecified in the protocol to include only participants in Part 2.

    Time frame: From the date of the first dose to the date of first objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurred first (up to approximately 22 months)

Secondary outcomes

  1. Objective Response Rate (ORR) - Part 1

    Objective Response Rate per investigator is the percentage of participants who have a confirmed complete or partial best overall response (BOR) among participants who have measurable disease at baseline. Complete Response (CR) is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to =\< 10 mm. Partial Response (PR) is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Baseline was defined as evaluations or events that occur before the date and time of the first dose of study treatment or evaluations on the same date and time of the first dose of study treatment were also considered as baseline evaluations. This endpoint was prespecified in the protocol to include only participants in Part 1.

    Time frame: From the date of the first dose to the date of first objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurred first (up to approximately 74 months)

  2. Duration of Response (DOR) - Part 1

    DOR for a participant with a best overall response (BOR) of CR or PR is defined as the date of first response up to the date of the first objectively documented tumor progression by the investigator per RECIST v1.1 or death, whichever occurs first. Analysis computed using Kaplan-Meier method. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to =\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of at least 5 mm. This endpoint was prespecified in the protocol to include only participants in Part 1.

    Time frame: From the date of the first dose to the date of first objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurred first (up to approximately 74 months)

  3. Maximum Concentration (Cmax) - Part 1

    Cmax is the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administered and before the administration of a second dose. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days)

    Time frame: Cycle 1 Day 1

  4. AUC(0-T)-Area Under Curve From Time Zero up to Last Quantifiable Concentration - Part 1

    AUC (0-T) represents the observed exposure to a drug (area under the concentration curve) from first exposure until the last quantifiable concentration. Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days)

    Time frame: 0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours post-dose on Cycle 1 Day 1

  5. AUC(TAU)-Area Under Curve in 1 Dosing Interval - Part 1

    Area under the concentration-time curve in 1 dosing interval. Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days)

    Time frame: Cycle 1 Day 1

  6. Observed Serum Concentration at the End of a Dosing Interval (Ctau) - Part 1

    BMS-986253 observed serum concentration at the end of a dosing interval (Ctau). Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint. 1 cycle=28 days for all Arms/Groups except Cycles 1 and 2 (1 cycle=42 days) in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group

    Time frame: Cycle 1 Day 1

  7. Total Body Clearance (CLT) - Part 1

    Clearance is the rate of elimination of BMS-986253 from the blood calculated as the rate of elimination divided by serum concentration. Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days)

    Time frame: Cycle 1 Day 1

  8. Average Serum Concentration Over a Dosing Interval (Css-avg) - Part 1

    BMS-986253 Average concentration over a dosing interval (\\\[AUC(TAU)/tau\\\] (Css-avg) at steady state. Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days) Note: C2D1, C3D1, C4D1 were partial samplings only as pre-specified in the protocol and did not include a sampling for each arm.

    Time frame: Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1

  9. AUC Accumulation Index (AI_AUC) - Part 1

    AUC Accumulation Index is defined as the ratio of AUC(TAU) at steady state to AUC(TAU) after the first dose. Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days) Note: C2D1, C3D1, C4D1 were partial samplings only as pre-specified in the protocol and did not include a sampling for each arm.

    Time frame: Cycle 2 Day 1, Cycle 3 Day 1, and Cycle 4 Day 1

  10. Cmax Accumulation Index (AI_Cmax) - Part 1

    BMS-986253 Cmax accumulation index (AI\_Cmax). Ratio of an exposure measure at steady state to that after the first dose. Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days) Note: C2D1, C3D1, C4D1 were partial samplings only as pre-specified in the protocol and did not include a sampling for each arm.

    Time frame: Cycle 2 Day 1, Cycle 3 Day 1, and Cycle 4 Day 1

  11. Ctau Accumulation Index (AI_Ctau) - Part 1

    Ctau is the observed serum concentration at the end of a dosing interval. Ctau accumulation index (AI\_Ctau) is the ratio of an exposure measure at steady state to that after the first dose. Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint. Ctau was reported on non-compartmental analysis day, which is on Cycle 1 Day1, Cycle 2 Day 1, Cycle 3 Day 1, or Cycle 4 Day 1 based on data available. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days) Note: C2D1, C3D1, C4D1 were partial samplings only as pre-specified in the protocol and did not include a sampling for each arm.

    Time frame: Cycle 2 Day 1, Cycle 3 Day 1, and Cycle 4 Day 1

  12. Effective Elimination (T-HALFeff) - Part 1

    BMS-986253 effective elimination (T-HALFeff) that explains the degree of accumulation observed for a specific exposure measure. Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days) Note: C2D1, C3D1, C4D1 were partial samplings only as pre-specified in the protocol and did not include a sampling for each arm.

    Time frame: Cycle 2 Day 1, Cycle 3 Day 1, and Cycle 4 Day 1

  13. Time to Maximum Concentration (Tmax) - Part 1

    Tmax is defined as the time it takes for a drug to reach the maximum concentration (Cmax) after administration of a drug. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days)

    Time frame: Cycle 1 Day 1

  14. Serum Trough Concentration (Ctrough) - Part 1

    A serum trough concentration (Ctrough) is the concentration reached by a drug immediately before the next dose is administered. Serum trough concentrations (Ctrough) of BMS-986253 will be summarized with descriptive statistics by treatment and visit. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days) Note: The timepoints listed were partial samplings only as pre-specified in the protocol and did not include a sampling for each arm.

    Time frame: C1D15, C1D29, C2D1, C2D9, C2D15, C3D1, C4D1, C4D15, C5D1, C7D1, C9D1, C10D1, C14D1, C20D1, and C26D1

  15. Number of Participants With Anti-Drug Antibodies (ADA) - Part 1

    Blood samples were evaluated for development of Anti-Drug Antibody (ADA) by a validated electrochemiluminescent (ECL) immunoassay. Baseline is defined as first dose. ADA-positive subject: A subject with at least one ADA positive-sample relative to baseline at any time after initiation of treatment. Persistent Positive (PP): ADA-positive sample at 2 or more consecutive time points, where the first and last ADA-positive samples are at least 16 weeks apart Not PP-Last Sample Positive: Not persistent positive with ADA-positive sample at the last sampling time point Other Positive: Not persistent positive but some ADA-positive samples with the last sample being negative Neutralizing Positive: At least one ADA-positive sample with neutralizing antibodies detected ADA-negative subject: A subject with no ADA-positive sample after the initiation of treatment. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days)

    Time frame: C1D1, C1D2, C1D8, C1D15, C1D22, C2D1, C2D2, C2D8, C2D15, C3D1, C4D1, C4D2, C4D8, C4D15, C4D22, C5D1, C9D1, C14D1, C20D1, C26D1, C32D1, C38D1, 30-day follow-up, 100-day follow-up

  16. Change From Baseline in Interleukin 8 (IL-8)- Part 1

    Change from baseline in IL-8 measured in pg/mL. Baseline is defined as first dose. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days) Note: Some timepoints were partial samplings only as pre-specified in the protocol and did not include a sampling for each arm.

    Time frame: C1D2, C1D8, C1D15, C1D22, C1D29, C1D36, C2D1, C2D2, C2D8, C2D15, C2D22, C2D29, C3D1, C3D2, C3D8, C4D1, C4D2, C4D8, C4D15, C4D22, C5D1, C7D1, C8D1, C9D1, C10D1, C11D1, C14D1, C16D1, C17D1, C20D1, C23D1, C26D1, at last dose, and 100 days post last dose

  17. Progression Free Survival (PFS) - Part 2

    Progression free survival (PFS) is defined for all randomized participants as the date from randomization to the date of the documentation of disease progression by BICR or death due to any cause, whichever is earlier. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression. This endpoint was prespecified in the protocol to include only participants in Part 2.

    Time frame: From the date of the first dose to the date of first objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurred first (up to approximately 22 months)

  18. Number of Participants Experiencing Adverse Events (AEs) - Part 2

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal. This endpoint was prespecified in the protocol to include only participants in Part 2.

    Time frame: From first dose up to 100 days after last dose (up to 25 months)

  19. Number of Participants Experiencing Serious Adverse Events (SAEs) - Part 2

    A serious adverse event is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is an important medical event.

    Time frame: From first dose up to 100 days after last dose (up to 25 months)

  20. Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation - Part 2

    Number of participants with any grade adverse events (AEs) leading to discontinuation of study treatment. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. Toxicities will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

    Time frame: From first dose up to 100 days after last dose (up to 25 months)

  21. Number of Participants Who Died - Part 2

    The number of participants who died due to any cause are summarized.

    Time frame: From first dose up to 100 days after last dose (up to 25 months)

  22. Most Frequently Reported Grade 3 and Grade 4 Laboratory Test Results - Part 2

    Laboratory results were graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Laboratory tests are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal. This endpoint was prespecified in the protocol to include only participants in Part 2.

    Time frame: From first dose up to 30 days after last dose (up to 23 months)

08

Results

Posted Jun 19, 2025

Participant flow

Pre-Treatment
Participant flow — Pre-Treatment
MilestonePart 1: 600 Q4WPart 1: 1200 Q4WPart 1: 2400 Q4WPart 1: 1200 Q2WPart 1: 2400 Q2WPart 1: 3600 Q2WPart 1: 3600Q2W + Nivo + IpiPart 2 Arm A: BMS+Nivo+IpiPart 2 Arm B: Placebo+Nivo+Ipi
Started161518126320156260
Randomized00000006260
Completed161518126320156257
Not completed000000003
Withdrew: Other reasons000000001
Withdrew: No longer met study criteria000000001
Withdrew: Withdrawal by subject000000001
Treatment
Participant flow — Treatment
MilestonePart 1: 600 Q4WPart 1: 1200 Q4WPart 1: 2400 Q4WPart 1: 1200 Q2WPart 1: 2400 Q2WPart 1: 3600 Q2WPart 1: 3600Q2W + Nivo + IpiPart 2 Arm A: BMS+Nivo+IpiPart 2 Arm B: Placebo+Nivo+Ipi
Started161518126320156257
Completed11101595114115849
Not completed5533126448
Withdrew: Participant withdrew consent220033111
Withdrew: Other reasons011031201
Withdrew: Lost to follow-up010000000
Withdrew: Death312362136

Outcome measures

PrimaryNumber of Participants Experiencing Adverse Events (AEs) - Part 1

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal. This endpoint was prespecified in the protocol to include only participants in Part 1.

Time frame:
From first dose up to 100 days after last dose (up to 65 months)
Reported as:
Count of participants · Participants
Number of Participants Experiencing Adverse Events (AEs) - Part 1
ParticipantsPart 1: 600 Q4WPart 1: 1200 Q4WPart 1: 2400 Q4WPart 1: 1200 Q2WPart 1: 2400 Q2WPart 1: 3600 Q2WPart 1: 3600Q2W + Nivo + Ipi
Number of Participants Experiencing Adverse Events (AEs) - Part 116141812602015
PrimaryNumber of Participants Experiencing Serious Adverse Events (SAEs) - Part 1

A serious adverse event is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is an important medical event. This endpoint was prespecified in the protocol to include only participants in Part 1.

Time frame:
From first dose up to 100 days after last dose (up to 65 months)
Reported as:
Count of participants · Participants
Number of Participants Experiencing Serious Adverse Events (SAEs) - Part 1
ParticipantsPart 1: 600 Q4WPart 1: 1200 Q4WPart 1: 2400 Q4WPart 1: 1200 Q2WPart 1: 2400 Q2WPart 1: 3600 Q2WPart 1: 3600Q2W + Nivo + Ipi
Number of Participants Experiencing Serious Adverse Events (SAEs) - Part 1131013731129
PrimaryNumber of Participants Experiencing Dose Limiting Toxicities (DLTs) - Part 1

Dose-Limiting Toxicities (DLTs) are effects of a treatment that are serious enough to prevent an increase in dose of that treatment, as advised by the Dose Review Team. DLTs will be defined based on the incidence, intensity, and duration of AEs that are possibly related to study treatment. DLTs will include gastrointestinal, hepatic, hematologic, dermatologic, and other AEs. This endpoint was prespecified in the protocol to include only participants in Part 1.

Time frame:
From first dose up to 100 days after last dose (up to 65 months)
Reported as:
Count of participants · Participants
Number of Participants Experiencing Dose Limiting Toxicities (DLTs) - Part 1
ParticipantsPart 1: 600 Q4WPart 1: 1200 Q4WPart 1: 2400 Q4WPart 1: 1200 Q2WPart 1: 2400 Q2WPart 1: 3600 Q2WPart 1: 3600Q2W + Nivo + Ipi
Number of Participants Experiencing Dose Limiting Toxicities (DLTs) - Part 10000000
PrimaryNumber of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation - Part 1

Number of participants with any grade adverse events (AEs) leading to discontinuation of study treatment. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. Toxicities will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. This endpoint was prespecified in the protocol to include only participants in Part 1.

Time frame:
From first dose up to 100 days after last dose (up to 65 months)
Reported as:
Count of participants · Participants
Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation - Part 1
ParticipantsPart 1: 600 Q4WPart 1: 1200 Q4WPart 1: 2400 Q4WPart 1: 1200 Q2WPart 1: 2400 Q2WPart 1: 3600 Q2WPart 1: 3600Q2W + Nivo + Ipi
Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation - Part 13233713
PrimaryNumber of Participants Who Died - Part 1

The number of participants who died due to any cause are summarized. This endpoint was prespecified in the protocol to include only participants in Part 1.

Time frame:
From first dose up to 100 days after last dose (up to 65 months)
Reported as:
Count of participants · Participants
Number of Participants Who Died - Part 1
ParticipantsPart 1: 600 Q4WPart 1: 1200 Q4WPart 1: 2400 Q4WPart 1: 1200 Q2WPart 1: 2400 Q2WPart 1: 3600 Q2WPart 1: 3600Q2W + Nivo + Ipi
Number of Participants Who Died - Part 11415171053138
PrimaryMost Frequently Reported Grade 3 and Grade 4 Laboratory Test Results - Part 1

Laboratory results were graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Laboratory tests are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal. This endpoint was prespecified in the protocol to include only participants in Part 1.

Time frame:
From first dose up to 30 days after last dose (up to 63 months)
Reported as:
Count of participants · Participants
Most Frequently Reported Grade 3 and Grade 4 Laboratory Test Results - Part 1
ParticipantsPart 1: 600 Q4WPart 1: 1200 Q4WPart 1: 2400 Q4WPart 1: 1200 Q2WPart 1: 2400 Q2WPart 1: 3600 Q2WPart 1: 3600Q2W + Nivo + Ipi
Hemoglobin - Grade 32122733
Alanine aminotransferase - Grade 30100002
Alkaline phosphatase - Grade 30020232
Aspartate aminotransferase - Grade 30100021
Phosphate - Grade 30120310
Sodium - Grade 30210512
Lipase - Grade 31121302
Lipase - Grade 40001202
Amylase - Grade 30010002
Amylase - Grade 40100000
Albumin - Grade 30030200
SecondaryObjective Response Rate (ORR) - Part 1

Objective Response Rate per investigator is the percentage of participants who have a confirmed complete or partial best overall response (BOR) among participants who have measurable disease at baseline. Complete Response (CR) is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to =\< 10 mm. Partial Response (PR) is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Baseline was defined as evaluations or events that occur before the date and time of the first dose of study treatment or evaluations on the same date and time of the first dose of study treatment were also considered as baseline evaluations. This endpoint was prespecified in the protocol to include only participants in Part 1.

Time frame:
From the date of the first dose to the date of first objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurred first (up to approximately 74 months)
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) - Part 1
Percentage of ParticipantsPart 1: 600 Q4WPart 1: 1200 Q4WPart 1: 2400 Q4WPart 1: 1200 Q2WPart 1: 2400 Q2WPart 1: 3600 Q2WPart 1: 3600Q2W + Nivo + Ipi
Objective Response Rate (ORR) - Part 16.3 (0.2 to 30.2)6.7 (0.2 to 31.9)16.7 (3.6 to 41.4)0 (0.0 to 26.5)3.2 (0.4 to 11.0)10.0 (1.2 to 31.7)13.3 (1.7 to 40.5)
SecondaryDuration of Response (DOR) - Part 1

DOR for a participant with a best overall response (BOR) of CR or PR is defined as the date of first response up to the date of the first objectively documented tumor progression by the investigator per RECIST v1.1 or death, whichever occurs first. Analysis computed using Kaplan-Meier method. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to =\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of at least 5 mm. This endpoint was prespecified in the protocol to include only participants in Part 1.

Time frame:
From the date of the first dose to the date of first objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurred first (up to approximately 74 months)
Reported as:
Median · Months
Duration of Response (DOR) - Part 1
MonthsPart 1: 600 Q4WPart 1: 1200 Q4WPart 1: 2400 Q4WPart 1: 1200 Q2WPart 1: 2400 Q2WPart 1: 3600 Q2WPart 1: 3600Q2W + Nivo + Ipi
Duration of Response (DOR) - Part 13.7 (3.7 to 3.7)28.9 (28.9 to 28.9)44.6 (8.4 to 44.6)—21.09 (4.0 to 21.1)3.4 (3.4 to 3.4)NA (3.7 to 24.0)
SecondaryMaximum Concentration (Cmax) - Part 1

Cmax is the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administered and before the administration of a second dose. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days)

Time frame:
Cycle 1 Day 1
Reported as:
Geometric mean · ug/mL
Maximum Concentration (Cmax) - Part 1
ug/mLPart 1: 600 Q4WPart 1: 1200 Q4WPart 1: 2400 Q4WPart 1: 1200 Q2WPart 1: 2400 Q2WPart 1: 3600 Q2WPart 1: 3600Q2W + Nivo + Ipi
Maximum Concentration (Cmax) - Part 1142.91 ± 52.1352.12 ± 62.7779.90 ± 43.1325.67 ± 24.0919.44 ± 32.81227.67 ± 23.3999.60 ± 29.4
SecondaryAUC(0-T)-Area Under Curve From Time Zero up to Last Quantifiable Concentration - Part 1

AUC (0-T) represents the observed exposure to a drug (area under the concentration curve) from first exposure until the last quantifiable concentration. Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days)

Time frame:
0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours post-dose on Cycle 1 Day 1
Reported as:
Geometric mean · h*ug/mL
AUC(0-T)-Area Under Curve From Time Zero up to Last Quantifiable Concentration - Part 1
h*ug/mLPart 1: 600 Q4WPart 1: 1200 Q4WPart 1: 2400 Q4WPart 1: 1200 Q2WPart 1: 2400 Q2WPart 1: 3600 Q2WPart 1: 3600Q2W + Nivo + Ipi
AUC(0-T)-Area Under Curve From Time Zero up to Last Quantifiable Concentration - Part 119594.22 ± 52.744821.39 ± 44.5105171.46 ± 29.742835.41 ± 28.1112123.35 ± 34.2148321.77 ± 32.0118041.10 ± 40.3
SecondaryAUC(TAU)-Area Under Curve in 1 Dosing Interval - Part 1

Area under the concentration-time curve in 1 dosing interval. Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days)

Time frame:
Cycle 1 Day 1
Reported as:
Geometric mean · h*ug/mL
AUC(TAU)-Area Under Curve in 1 Dosing Interval - Part 1
h*ug/mLPart 1: 600 Q4WPart 1: 1200 Q4WPart 1: 2400 Q4WPart 1: 1200 Q2WPart 1: 2400 Q2WPart 1: 3600 Q2WPart 1: 3600Q2W + Nivo + Ipi
AUC(TAU)-Area Under Curve in 1 Dosing Interval - Part 121301.74 ± 49.548664.06 ± 42.9106916.11 ± 27.343844.97 ± 24.8113969.47 ± 30.8153791.84 ± 27.9137809.44 ± 29.5
SecondaryObserved Serum Concentration at the End of a Dosing Interval (Ctau) - Part 1

BMS-986253 observed serum concentration at the end of a dosing interval (Ctau). Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint. 1 cycle=28 days for all Arms/Groups except Cycles 1 and 2 (1 cycle=42 days) in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group

Time frame:
Cycle 1 Day 1
Reported as:
Geometric mean · ug/mL
Observed Serum Concentration at the End of a Dosing Interval (Ctau) - Part 1
ug/mLPart 1: 600 Q4WPart 1: 1200 Q4WPart 1: 2400 Q4WPart 1: 1200 Q2WPart 1: 2400 Q2WPart 1: 3600 Q2WPart 1: 3600Q2W + Nivo + Ipi
Observed Serum Concentration at the End of a Dosing Interval (Ctau) - Part 16.81 ± 173.814.92 ± 144.423.68 ± 692.455.82 ± 53.0141.89 ± 42.6181.84 ± 46.3175.29 ± 46.6
SecondaryTotal Body Clearance (CLT) - Part 1

Clearance is the rate of elimination of BMS-986253 from the blood calculated as the rate of elimination divided by serum concentration. Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days)

Time frame:
Cycle 1 Day 1
Reported as:
Geometric mean · mL/h
Total Body Clearance (CLT) - Part 1
mL/hPart 1: 600 Q4WPart 1: 1200 Q4WPart 1: 2400 Q4WPart 1: 1200 Q2WPart 1: 2400 Q2WPart 1: 3600 Q2WPart 1: 3600Q2W + Nivo + Ipi
Total Body Clearance (CLT) - Part 128.17 ± 49.524.66 ± 42.922.45 ± 27.327.37 ± 24.821.06 ± 30.823.41 ± 27.926.12 ± 29.5
SecondaryAverage Serum Concentration Over a Dosing Interval (Css-avg) - Part 1

BMS-986253 Average concentration over a dosing interval (\\\[AUC(TAU)/tau\\\] (Css-avg) at steady state. Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days) Note: C2D1, C3D1, C4D1 were partial samplings only as pre-specified in the protocol and did not include a sampling for each arm.

Time frame:
Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1
Reported as:
Geometric mean · ug/mL
Average Serum Concentration Over a Dosing Interval (Css-avg) - Part 1
ug/mLPart 1: 600 Q4WPart 1: 1200 Q4WPart 1: 2400 Q4WPart 1: 1200 Q2WPart 1: 2400 Q2WPart 1: 3600 Q2WPart 1: 3600Q2W + Nivo + Ipi
C2D1———182.48 ± 26.6487.85 ± 32.4658.06 ± 26.2397.96 ± 32.7
C3D159.03 ± 47.166.87 ± 74.2181.94 ± 19.0————
C4D1—115.89—238.51 ± 20.1535.44 ± 37.4590.45 ± 37.5—
SecondaryAUC Accumulation Index (AI_AUC) - Part 1

AUC Accumulation Index is defined as the ratio of AUC(TAU) at steady state to AUC(TAU) after the first dose. Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days) Note: C2D1, C3D1, C4D1 were partial samplings only as pre-specified in the protocol and did not include a sampling for each arm.

Time frame:
Cycle 2 Day 1, Cycle 3 Day 1, and Cycle 4 Day 1
Reported as:
Geometric mean · Ratio
AUC Accumulation Index (AI_AUC) - Part 1
RatioPart 1: 600 Q4WPart 1: 1200 Q4WPart 1: 2400 Q4WPart 1: 1200 Q2WPart 1: 2400 Q2WPart 1: 3600 Q2WPart 1: 3600Q2W + Nivo + Ipi
C2D1———1.45 ± 10.31.40 ± 22.81.34 ± 20.61.19 ± 6.6
C3D11.47 ± 37.41.07 ± 16.81.08 ± 15.7————
C4D1—1.30—1.77 ± 20.01.64 ± 17.21.43 ± 7.1—
SecondaryCmax Accumulation Index (AI_Cmax) - Part 1

BMS-986253 Cmax accumulation index (AI\_Cmax). Ratio of an exposure measure at steady state to that after the first dose. Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days) Note: C2D1, C3D1, C4D1 were partial samplings only as pre-specified in the protocol and did not include a sampling for each arm.

Time frame:
Cycle 2 Day 1, Cycle 3 Day 1, and Cycle 4 Day 1
Reported as:
Geometric mean · Ratio
Cmax Accumulation Index (AI_Cmax) - Part 1
RatioPart 1: 600 Q4WPart 1: 1200 Q4WPart 1: 2400 Q4WPart 1: 1200 Q2WPart 1: 2400 Q2WPart 1: 3600 Q2WPart 1: 3600Q2W + Nivo + Ipi
C2D1———1.15 ± 16.71.11 ± 36.51.21 ± 18.61.15 ± 28.3
C3D10.90 ± 81.61.05 ± 16.90.86 ± 35.5————
C4D11.581.19—1.63 ± 46.01.36 ± 26.30.98 ± 30.9—
SecondaryCtau Accumulation Index (AI_Ctau) - Part 1

Ctau is the observed serum concentration at the end of a dosing interval. Ctau accumulation index (AI\_Ctau) is the ratio of an exposure measure at steady state to that after the first dose. Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint. Ctau was reported on non-compartmental analysis day, which is on Cycle 1 Day1, Cycle 2 Day 1, Cycle 3 Day 1, or Cycle 4 Day 1 based on data available. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days) Note: C2D1, C3D1, C4D1 were partial samplings only as pre-specified in the protocol and did not include a sampling for each arm.

Time frame:
Cycle 2 Day 1, Cycle 3 Day 1, and Cycle 4 Day 1
Reported as:
Geometric mean · Ratio
Ctau Accumulation Index (AI_Ctau) - Part 1
RatioPart 1: 600 Q4WPart 1: 1200 Q4WPart 1: 2400 Q4WPart 1: 1200 Q2WPart 1: 2400 Q2WPart 1: 3600 Q2WPart 1: 3600Q2W + Nivo + Ipi
C2D1———1.90 ± 22.71.51 ± 38.01.39 ± 30.71.10 ± 21.2
C3D11.33 ± 91.01.29 ± 6.50.90 ± 53.5————
C4D1—1.35—1.97 ± 31.52.01 ± 35.51.37 ± 45.2—
SecondaryEffective Elimination (T-HALFeff) - Part 1

BMS-986253 effective elimination (T-HALFeff) that explains the degree of accumulation observed for a specific exposure measure. Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days) Note: C2D1, C3D1, C4D1 were partial samplings only as pre-specified in the protocol and did not include a sampling for each arm.

Time frame:
Cycle 2 Day 1, Cycle 3 Day 1, and Cycle 4 Day 1
Reported as:
Mean · Hours
Effective Elimination (T-HALFeff) - Part 1
HoursPart 1: 600 Q4WPart 1: 1200 Q4WPart 1: 2400 Q4WPart 1: 1200 Q2WPart 1: 2400 Q2WPart 1: 3600 Q2WPart 1: 3600Q2W + Nivo + Ipi
C2D1———200.10 ± 39.12202.89 ± 76.38185.51 ± 71.51145.15 ± 51.41
C3D1410.31 ± 275.42222.95 ± 92.65240.94 ± 92.57————
C4D1—317.87—283.97 ± 84.38247.68 ± 73.44189.42 ± 22.08—
SecondaryTime to Maximum Concentration (Tmax) - Part 1

Tmax is defined as the time it takes for a drug to reach the maximum concentration (Cmax) after administration of a drug. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days)

Time frame:
Cycle 1 Day 1
Reported as:
Median · Hours
Time to Maximum Concentration (Tmax) - Part 1
HoursPart 1: 600 Q4WPart 1: 1200 Q4WPart 1: 2400 Q4WPart 1: 1200 Q2WPart 1: 2400 Q2WPart 1: 3600 Q2WPart 1: 3600Q2W + Nivo + Ipi
Time to Maximum Concentration (Tmax) - Part 13.95 (1.0 to 24.0)1.00 (0.9 to 4.1)3.81 (2.0 to 6.1)4.00 (0.9 to 4.2)4.00 (1.0 to 23.5)2.18 (1.9 to 21.1)1.99 (1.9 to 21.8)
SecondarySerum Trough Concentration (Ctrough) - Part 1

A serum trough concentration (Ctrough) is the concentration reached by a drug immediately before the next dose is administered. Serum trough concentrations (Ctrough) of BMS-986253 will be summarized with descriptive statistics by treatment and visit. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days) Note: The timepoints listed were partial samplings only as pre-specified in the protocol and did not include a sampling for each arm.

Time frame:
C1D15, C1D29, C2D1, C2D9, C2D15, C3D1, C4D1, C4D15, C5D1, C7D1, C9D1, C10D1, C14D1, C20D1, and C26D1
Reported as:
Geometric mean · ng/mL
Serum Trough Concentration (Ctrough) - Part 1
ng/mLPart 1: 600 Q4WPart 1: 1200 Q4WPart 1: 2400 Q4WPart 1: 1200 Q2WPart 1: 2400 Q2WPart 1: 3600 Q2WPart 1: 3600Q2W + Nivo + Ipi
C1D15 - Predose———59518.0 ± 49.4149309.4 ± 37.0221414.7 ± 26.0166358.6 ± 43.2
C1D29 - Predose——————242843.4 ± 65.2
C2D1 - Predose10711.8 ± 124.614450.3 ± 177.545153.8 ± 50.485596.2 ± 38.1187079.9 ± 47.5272401.3 ± 54.1194945.1 ± 35.3
C2D15 - Predose———98349.7 ± 46.0226385.2 ± 44.5299360.3 ± 44.3112012.1 ± 37.6
C2D29 - Predose——————160198.5 ± 38.2
C3D1 - Predose12124.7 ± 82.521260.6 ± 131.958149.8 ± 31.592359.7 ± 35.7224533.3 ± 54.9260971.3 ± 63.9113514.3 ± 12.4
C4D1 - Predose27124.2 ± 99.115763.7 ± 219.254841.7 ± 43.686790.7 ± 41.8271535.1 ± 44.9327146.5 ± 55.7145940.5 ± 19.8
C4D15 - Predose———127803.1 ± 24.5258413.8 ± 48.1356070.0 ± 56.9—
C5D1 - Predose—34491.0—125274.8 ± 27.4161340.5 ± 551.8312899.5 ± 65.2—
C7D1 - Predose29506.051155.076154.6 ± 26.5————
C9D1 - Predose——48706.0182098.0 ± 43.0263195.0 ± 56.6281410.5 ± 85.2—
C10D1 - Predose——94273.0————
C14D1 - Predose—95722.0102905.0200795.9 ± 27.5298491.4 ± 50.2361774.6 ± 41.4—
C20D1 - Predose—72607.0116745.081342.0424725.7 ± 23.5427000.0—
C26D1 - Predose—56040.0143209.5 ± 14.8————
SecondaryNumber of Participants With Anti-Drug Antibodies (ADA) - Part 1

Blood samples were evaluated for development of Anti-Drug Antibody (ADA) by a validated electrochemiluminescent (ECL) immunoassay. Baseline is defined as first dose. ADA-positive subject: A subject with at least one ADA positive-sample relative to baseline at any time after initiation of treatment. Persistent Positive (PP): ADA-positive sample at 2 or more consecutive time points, where the first and last ADA-positive samples are at least 16 weeks apart Not PP-Last Sample Positive: Not persistent positive with ADA-positive sample at the last sampling time point Other Positive: Not persistent positive but some ADA-positive samples with the last sample being negative Neutralizing Positive: At least one ADA-positive sample with neutralizing antibodies detected ADA-negative subject: A subject with no ADA-positive sample after the initiation of treatment. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days)

Time frame:
C1D1, C1D2, C1D8, C1D15, C1D22, C2D1, C2D2, C2D8, C2D15, C3D1, C4D1, C4D2, C4D8, C4D15, C4D22, C5D1, C9D1, C14D1, C20D1, C26D1, C32D1, C38D1, 30-day follow-up, 100-day follow-up
Reported as:
Count of participants · Participants
Number of Participants With Anti-Drug Antibodies (ADA) - Part 1
ParticipantsPart 1: 600 Q4WPart 1: 1200 Q4WPart 1: 2400 Q4WPart 1: 1200 Q2WPart 1: 2400 Q2WPart 1: 3600 Q2WPart 1: 3600Q2W + Nivo + Ipi
Baseline ADA positive0101100
ADA Positive-Overall3240201
ADA Persistent Positive (PP)0000000
ADA Positive-Not PP last sample positive2110200
ADA Positive-other positive1130001
ADA Negative129121152157
SecondaryChange From Baseline in Interleukin 8 (IL-8)- Part 1

Change from baseline in IL-8 measured in pg/mL. Baseline is defined as first dose. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days) Note: Some timepoints were partial samplings only as pre-specified in the protocol and did not include a sampling for each arm.

Time frame:
C1D2, C1D8, C1D15, C1D22, C1D29, C1D36, C2D1, C2D2, C2D8, C2D15, C2D22, C2D29, C3D1, C3D2, C3D8, C4D1, C4D2, C4D8, C4D15, C4D22, C5D1, C7D1, C8D1, C9D1, C10D1, C11D1, C14D1, C16D1, C17D1, C20D1, C23D1, C26D1, at last dose, and 100 days post last dose
Reported as:
Mean · pg/mL
Change From Baseline in Interleukin 8 (IL-8)- Part 1
pg/mLPart 1: 600 Q4WPart 1: 1200 Q4WPart 1: 2400 Q4WPart 1: 1200 Q2WPart 1: 2400 Q2WPart 1: 3600 Q2WPart 1: 3600Q2W + Nivo + Ipi
Cycle 1 Day 2-96.9 (-891.0 to -24.3)-37.3 (-105.6 to -7.0)-66.3 (-377.0 to -5.8)-48.2 (-115.5 to -21.6)-48.5 (-141.5 to -4.4)-82.8 (-509.6 to -8.2)-76.1 (-268.2 to -18.6)
Cycle 1 Day 8-78.2 (-857.0 to -5.0)-31.4 (-94.0 to -6.2)-58.6 (-350.0 to -4.8)-40.3 (-107.0 to -17.2)-69.8 (-1569.6 to 2.2)-48.1 (-121.0 to -5.0)-71.9 (-246.0 to -6.0)
Cycle 1 Day 15-66.2 (-769.0 to 11.0)-24.4 (-79.0 to 3.0)-34.3 (-87.0 to -0.3)-23.6 (-63.0 to -11.0)-38.0 (-123.2 to 89.0)-65.8 (-502.5 to -1.0)-33.5 (-120.0 to -3.0)
Cycle 1 Day 22-48.0 (-561.0 to 24.0)17.4 (-30.8 to 277.0)-41.6 (-240.0 to 11.8)-33.0 (-77.0 to -18.6)-71.3 (-1559.0 to 1.7)-68.1 (-507.2 to -8.2)-34.3 (-104.0 to -6.0)
Cycle 1 Day 29——————-23.2 (-62.9 to -4.0)
Cycle 1 Day 36——————-29.1 (-66.8 to -10.2)
Cycle 2 Day 13.8 (-67.0 to 50.0)43.5 (-28.0 to 427.0)-20.3 (-73.0 to 32.8)-25.3 (-58.0 to -5.0)-40.2 (-127.8 to 4.0)-78.3 (-506.1 to -9.0)-21.3 (-65.5 to 23.0)
Cycle 2 Day 2———-42.5 (-84.0 to -21.6)-47.3 (-139.4 to 0.0)-48.2 (-127.1 to -8.2)-31.5 (-68.6 to -7.7)
Cycle 2 Day 8———-35.6 (-77.0 to -18.6)-44.2 (-136.8 to 0.6)-77.4 (-508.2 to -8.2)-26.1 (-68.0 to -5.5)
Cycle 2 Day 15-22.6 (-99.0 to -3.0)-13.8 (-30.8 to 3.0)-30.0 (-70.0 to 6.8)-31.0 (-63.0 to -17.4)-70.8 (-1569.1 to 3.1)-74.6 (-501.3 to -7.4)9.1 (-22.2 to 56.0)
Cycle 2 Day 22——————-18.7 (-29.4 to -2.8)
Cycle 2 Day 29——————-22.7 (-26.9 to -18.0)
Cycle 3 Day 12.0 (-82.0 to 44.0)-4.0 (-25.0 to 30.0)-16.4 (-49.0 to 21.0)-25.1 (-38.0 to -8.0)-86.7 (-1569.6 to 2.3)-93.5 (-508.2 to -8.1)-14.4 (-21.0 to 4.0)
Cycle 3 Day 2————-24.9 (-24.9 to -24.9)——
Cycle 3 Day 8-36.3 (-113.0 to -7.0)-24.5 (-34.5 to -15.0)-37.0 (-77.0 to -13.2)————
Cycle 3 Day 15-44.3 (-117.0 to -2.0)-20.8 (-31.7 to -14.0)-24.3 (-46.8 to -5.0)————
Cycle 3 Day 22-53.5 (-107.0 to 0.0)-15.4 (-27.0 to -2.0)-16.9 (-43.0 to 23.0)————
Cycle 4 Day 1-30.3 (-101.0 to 18.0)-8.8 (-26.0 to 13.0)-15.5 (-28.4 to 3.5)-18.5 (-38.9 to 1.0)-102.9 (-1568.8 to 2.0)-29.6 (-86.0 to 9.0)-23.8 (-26.4 to -21.1)
Cycle 4 Day 2—-35.7 (-35.7 to -35.7)—-32.0 (-41.7 to -21.3)-33.5 (-81.6 to 0.5)-44.0 (-96.9 to -13.6)—
Cycle 4 Day 8—-32.1 (-32.1 to -32.1)—-30.3 (-40.9 to -19.6)-32.7 (-81.6 to 3.8)-43.8 (-92.1 to -8.2)—
Cycle 4 Day 15—-29.0 (-29.0 to -29.0)—-26.7 (-38.6 to -17.6)-34.5 (-122.5 to 6.0)-46.4 (-90.6 to -8.2)—
Cycle 4 Day 22—-26.0 (-26.0 to -26.0)—-28.8 (-38.5 to -19.1)-30.6 (-81.1 to 2.7)-43.8 (-94.5 to -7.6)—
Cycle 5 Day 138.0 (38.0 to 38.0)——-27.3 (-36.0 to -17.7)-28.2 (-80.3 to 4.9)-46.8 (-91.7 to -8.2)—
Cycle 7 Day 1-111.0 (-111.0 to -111.0)-8.0 (-25.0 to 9.0)-14.6 (-29.7 to -1.7)-29.3 (-38.5 to -20.0)-33.0 (-80.8 to -13.6)-36.9 (-86.6 to -8.2)—
Cycle 8 Day 1——-21.8 (-21.8 to -21.8)————
Cycle 9 Day 1——-17.0 (-17.0 to -17.0)-28.2 (-38.5 to -18.6)-27.8 (-48.3 to -13.6)-9.1 (-11.0 to -7.1)—
Cycle 10 Day 1——-14.2 (-32.3 to 0.7)————
Cycle 11 Day 1—-16.0 (-28.0 to -4.0)—-30.7 (-37.7 to -21.4)-24.4 (-39.5 to -13.6)-7.6 (-7.6 to -7.6)—
Cycle 14 Day 1—-16.1 (-36.2 to 4.0)-2.2 (-2.2 to -2.2)-1.6 (-36.8 to 48.0)-22.2 (-38.2 to -13.6)——
Cycle 16 Day 1——-1.6 (-1.6 to -1.6)————
Cycle 17 Day 1—-32.2 (-32.2 to -32.2)-17.3 (-30.5 to -4.1)-38.0 (-38.0 to -38.0)-14.2 (-14.8 to -13.6)——
Cycle 20 Day 1—-30.7 (-30.7 to -30.7)-32.5 (-32.5 to -32.5)-34.4 (-34.4 to -34.4)-17.1 (-23.6 to -13.6)——
Cycle 23 Day 1—-28.9 (-28.9 to -28.9)-27.1 (-32.2 to -22.0)—-22.6 (-22.6 to -22.6)——
Cycle 26 Day 1—-30.8 (-30.8 to -30.8)-10.0 (-22.6 to 2.5)————
End of Treatment-44.0 (-105.0 to 17.0)—-49.5 (-66.0 to -29.0)-24.6 (-37.0 to -10.0)-34.5 (-125.0 to 20.0)-149.1 (-503.2 to -16.0)-50.9 (-65.0 to -36.8)
Follow-up 1——17.5 (9.0 to 26.0)————
PrimaryObjective Response Rate (ORR) - Part 2

Objective Response Rate per blinded independent central review (BICR) is the percentage of participants who have a confirmed complete or partial best overall response (BOR) among participants who have measurable disease at baseline. Complete Response (CR) is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to =\< 10 mm. Partial Response (PR) is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Baseline was defined as evaluations or events that occur before the date and time of the first dose of study treatment or evaluations on the same date and time of the first dose of study treatment were also considered as baseline evaluations. This endpoint was prespecified in the protocol to include only participants in Part 2.

Time frame:
From the date of the first dose to the date of first objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurred first (up to approximately 22 months)
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) - Part 2
Percentage of ParticipantsPart 2 Arm A: BMS+Nivo+IpiPart 2 Arm B: Placebo+Nivo+Ipi
Objective Response Rate (ORR) - Part 214.5 (6.9 to 25.8)11.7 (4.8 to 22.6)
SecondaryProgression Free Survival (PFS) - Part 2

Progression free survival (PFS) is defined for all randomized participants as the date from randomization to the date of the documentation of disease progression by BICR or death due to any cause, whichever is earlier. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression. This endpoint was prespecified in the protocol to include only participants in Part 2.

Time frame:
From the date of the first dose to the date of first objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurred first (up to approximately 22 months)
Reported as:
Median · Months
Progression Free Survival (PFS) - Part 2
MonthsPart 2 Arm A: BMS+Nivo+IpiPart 2 Arm B: Placebo+Nivo+Ipi
Progression Free Survival (PFS) - Part 22.103 (1.873 to 3.778)3.318 (1.906 to 3.745)
Statistical analysis
  • Part 2 Arm A: BMS+Nivo+Ipi vs Part 2 Arm B: Placebo+Nivo+Ipi · Log Rank · p = 0.7416 · Hazard ratio, log: 0.94 · 95% CI 0.61 to 1.45
SecondaryNumber of Participants Experiencing Adverse Events (AEs) - Part 2

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal. This endpoint was prespecified in the protocol to include only participants in Part 2.

Time frame:
From first dose up to 100 days after last dose (up to 25 months)
Reported as:
Count of participants · Participants
Number of Participants Experiencing Adverse Events (AEs) - Part 2
ParticipantsPart 2 Arm A: BMS+Nivo+IpiPart 2 Arm B: Placebo+Nivo+Ipi
Number of Participants Experiencing Adverse Events (AEs) - Part 26256
SecondaryNumber of Participants Experiencing Serious Adverse Events (SAEs) - Part 2

A serious adverse event is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is an important medical event.

Time frame:
From first dose up to 100 days after last dose (up to 25 months)
Reported as:
Count of participants · Participants
Number of Participants Experiencing Serious Adverse Events (SAEs) - Part 2
ParticipantsPart 2 Arm A: BMS+Nivo+IpiPart 2 Arm B: Placebo+Nivo+Ipi
Number of Participants Experiencing Serious Adverse Events (SAEs) - Part 24442
SecondaryNumber of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation - Part 2

Number of participants with any grade adverse events (AEs) leading to discontinuation of study treatment. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. Toxicities will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

Time frame:
From first dose up to 100 days after last dose (up to 25 months)
Reported as:
Count of participants · Participants
Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation - Part 2
ParticipantsPart 2 Arm A: BMS+Nivo+IpiPart 2 Arm B: Placebo+Nivo+Ipi
Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation - Part 21623
SecondaryNumber of Participants Who Died - Part 2

The number of participants who died due to any cause are summarized.

Time frame:
From first dose up to 100 days after last dose (up to 25 months)
Reported as:
Count of participants · Participants
Number of Participants Who Died - Part 2
ParticipantsPart 2 Arm A: BMS+Nivo+IpiPart 2 Arm B: Placebo+Nivo+Ipi
Number of Participants Who Died - Part 23017
SecondaryMost Frequently Reported Grade 3 and Grade 4 Laboratory Test Results - Part 2

Laboratory results were graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Laboratory tests are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal. This endpoint was prespecified in the protocol to include only participants in Part 2.

Time frame:
From first dose up to 30 days after last dose (up to 23 months)
Reported as:
Count of participants · Participants
Most Frequently Reported Grade 3 and Grade 4 Laboratory Test Results - Part 2
ParticipantsPart 2 Arm A: BMS+Nivo+IpiPart 2 Arm B: Placebo+Nivo+Ipi
Alanine aminotransferase - Grade 346
Alanine aminotransferase - Grade 421
Aspartate aminotransferase - Grade 333
Aspartate aminotransferase - Grade 410
Phosphate - Grade 333
Sodium - Grade 368
Sodium - Grade 420
Lipase - Grade 345
Lipase - Grade 455
Amylase - Grade 334

Adverse events

Collected over Participants were assessed for all-cause mortality from their first dose to their study completion (up to approximately 74 months). SAEs and Other AEs were assessed from first dose to 100 days post the last dose (up to approximately 65 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: 600 Q4W14/16 (87.5%)13/16 (81.3%)16/16 (100%)
Part 1: 1200 Q4W15/15 (100%)10/15 (66.7%)14/15 (93.3%)
Part 1: 2400 Q4W17/18 (94.4%)13/18 (72.2%)18/18 (100%)
Part 1: 1200 Q2W10/12 (83.3%)7/12 (58.3%)11/12 (91.7%)
Part 1: 2400 Q2W53/63 (84.1%)31/63 (49.2%)59/63 (93.7%)
Part 1: 3600 Q2W13/20 (65%)12/20 (60%)19/20 (95%)
Part 1: 3600Q2W + Nivo + Ipi8/15 (53.3%)9/15 (60%)15/15 (100%)
Part 2 Arm A: BMS+Nivo+Ipi30/62 (48.4%)44/62 (71%)61/62 (98.4%)
Part 2 Arm B: Placebo+Nivo+Ipi17/60 (28.3%)42/57 (73.7%)54/57 (94.7%)
Most frequent serious events
Showing 10 of 146
Most frequent serious events
EventPart 1: 600 Q4WPart 1: 1200 Q4WPart 1: 2400 Q4WPart 1: 1200 Q2WPart 1: 2400 Q2WPart 1: 3600 Q2WPart 1: 3600Q2W + Nivo + IpiPart 2 Arm A: BMS+Nivo+IpiPart 2 Arm B: Placebo+Nivo+Ipi
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)5/164/158/185/1217/636/204/156/6210/57
DysphagiaGastrointestinal disorders0/162/150/180/120/630/200/150/620/57
PyrexiaGeneral disorders0/160/150/180/120/630/202/152/623/57
DyspnoeaRespiratory, thoracic and mediastinal disorders2/161/151/180/124/630/201/151/622/57
ColitisGastrointestinal disorders0/160/151/180/120/630/201/154/627/57
PneumoniaInfections and infestations1/161/152/181/126/631/200/150/623/57
HaemoptysisRespiratory, thoracic and mediastinal disorders0/160/152/180/122/630/200/150/620/57
HypoxiaRespiratory, thoracic and mediastinal disorders0/160/152/180/120/630/200/150/620/57
General physical health deteriorationGeneral disorders0/160/150/180/122/632/200/152/621/57
Large intestinal obstructionGastrointestinal disorders0/160/150/181/120/630/200/150/620/57
Most frequent other events
Showing 10 of 267
Most frequent other events
EventPart 1: 600 Q4WPart 1: 1200 Q4WPart 1: 2400 Q4WPart 1: 1200 Q2WPart 1: 2400 Q2WPart 1: 3600 Q2WPart 1: 3600Q2W + Nivo + IpiPart 2 Arm A: BMS+Nivo+IpiPart 2 Arm B: Placebo+Nivo+Ipi
FatigueGeneral disorders6/166/156/183/1223/639/203/1515/6222/57
DiarrhoeaGastrointestinal disorders1/163/152/182/1214/636/205/1527/6225/57
AnaemiaBlood and lymphatic system disorders3/162/155/182/1216/637/206/1521/6214/57
PyrexiaGeneral disorders1/162/153/181/1211/635/202/1522/6216/57
ConstipationGastrointestinal disorders3/165/154/181/129/635/201/1513/6212/57
NauseaGastrointestinal disorders3/165/154/184/1215/635/203/1520/6218/57
Decreased appetiteMetabolism and nutrition disorders5/160/154/180/1221/633/204/1512/6212/57
DyspnoeaRespiratory, thoracic and mediastinal disorders5/165/153/183/129/631/202/159/626/57
PruritusSkin and subcutaneous tissue disorders0/161/150/181/1212/632/201/1518/6218/57
AstheniaGeneral disorders2/162/150/182/129/633/202/1518/625/57

Baseline characteristics

All treated participants for Part 1 and all randomized participants for Part 2. Participants in Part 1 were not randomized.

Age, Continuous
Age, Continuous(Years)Part 1: 600 Q4WPart 1: 1200 Q4WPart 1: 2400 Q4WPart 1: 1200 Q2WPart 1: 2400 Q2WPart 1: 3600 Q2WPart 1: 3600Q2W + Nivo + IpiPart 2 Arm A: BMS+Nivo+IpiPart 2 Arm B: Placebo+Nivo+IpiTotal
Mean60.4 (35.0 to 86.0)64.6 (49.0 to 83.0)66.3 (40.0 to 82.0)64.4 (51.0 to 87.0)63.0 (43.0 to 86.0)62.6 (36.0 to 78.0)56.6 (32.0 to 79.0)62.3 (22.0 to 89.0)60.6 (22.0 to 83.0)62.2 (22.0 to 89.0)
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: 600 Q4WPart 1: 1200 Q4WPart 1: 2400 Q4WPart 1: 1200 Q2WPart 1: 2400 Q2WPart 1: 3600 Q2WPart 1: 3600Q2W + Nivo + IpiPart 2 Arm A: BMS+Nivo+IpiPart 2 Arm B: Placebo+Nivo+IpiTotal
Female54551875221788
Male11111374513104043193
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: 600 Q4WPart 1: 1200 Q4WPart 1: 2400 Q4WPart 1: 1200 Q2WPart 1: 2400 Q2WPart 1: 3600 Q2WPart 1: 3600Q2W + Nivo + IpiPart 2 Arm A: BMS+Nivo+IpiPart 2 Arm B: Placebo+Nivo+IpiTotal
Hispanic or Latino0210400018
Not Hispanic or Latino16131794013104241201
Unknown or Not Reported00031975201872
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: 600 Q4WPart 1: 1200 Q4WPart 1: 2400 Q4WPart 1: 1200 Q2WPart 1: 2400 Q2WPart 1: 3600 Q2WPart 1: 3600Q2W + Nivo + IpiPart 2 Arm A: BMS+Nivo+IpiPart 2 Arm B: Placebo+Nivo+IpiTotal
American Indian or Alaska Native0000100001
Asian0001010013
Native Hawaiian or Other Pacific Islander0000000000
Black or African American1200211007
White151318115918135653256
More than one race0000000000
Unknown or Not Reported00001016614
09

Study locations

72 sites
  • Local Institution - 0059
    Springdale, Arkansas 72762, United States
  • Local Institution - 0099
    Los Angeles, California 90033, United States
  • Local Institution - 0007
    Lakewood, Colorado 80228, United States
  • Local Institution - 0087
    Atlanta, Georgia 30322, United States
  • Local Institution - 0100
    Atlanta, Georgia 30342, United States
  • Local Institution - 0101
    Marietta, Georgia 30060, United States
  • Local Institution - 0012
    Columbia, Maryland 21044, United States
  • Local Institution - 0003
    Lutherville, Maryland 21093, United States
  • Local Institution - 0060
    Boston, Massachusetts 02215, United States
  • Local Institution - 0004
    Ann Arbor, Michigan 48109, United States
  • Local Institution - 0076
    Omaha, Nebraska 68130, United States
  • Comprehensive Cancer Centers Of Nevada
    Las Vegas, Nevada 89169, United States
  • Local Institution - 0005
    Hackensack, New Jersey 07601, United States
  • Local Institution - 0032
    New Brunswick, New Jersey 08903, United States
  • Local Institution - 0025
    New York, New York 10029, United States
  • Local Institution - 0002
    New York, New York 10032, United States
  • Local Institution - 0028
    Oklahoma City, Oklahoma 73104, United States
  • Local Institution - 0017
    Eugene, Oregon 97401, United States
  • Local Institution - 0001
    Pittsburgh, Pennsylvania 15213, United States
  • Local Institution - 0009
    Greenville, South Carolina 29615, United States
  • Local Institution - 0011
    Austin, Texas 78705, United States
  • Local Institution - 0010
    Dallas, Texas 75246, United States
  • Local Institution - 0014
    Fort Worth, Texas 76104-3927, United States
  • Local Institution - 0018
    Houston, Texas 77030, United States
  • Local Institution - 0006
    San Antonio, Texas 78240, United States
  • Local Institution - 0013
    Tyler, Texas 75702, United States
  • Local Institution - 0058
    Salt Lake City, Utah 84112, United States
  • Local Institution - 0015
    Fairfax, Virginia 22031, United States
  • Local Institution - 0008
    Norfolk, Virginia 23502, United States
  • Local Institution - 0088
    Wollstonecraft, New South Wales 2065, Australia
  • Local Institution - 0096
    Adelaide, South Australia 5000, Australia
  • Local Institution - 0090
    Melbourne, Victoria 3000, Australia
  • Local Institution - 0095
    Melbourne, Victoria 3004, Australia
  • Local Institution - 0097
    Perth, Western Australia 6009, Australia
  • Local Institution - 0091
    Ballarat Central, VIC 3350, Australia
  • Local Institution - 0037
    Brussels, 1200, Belgium
  • Local Institution - 0036
    Ghent, 9000, Belgium
  • Local Institution - 0082
    Kortrijk, 8500, Belgium
  • Local Institution - 0030
    Edmonton, Alberta T6G 1Z2, Canada
  • Local Institution - 0029
    Vancouver, British Columbia V5Z 4E6, Canada
  • Local Institution - 0078
    Victoria, British Columbia V8R 6V5, Canada
  • Local Institution - 0020
    Toronto, Ontario M5G 1Z5, Canada
  • Local Institution - 0055
    Toronto, Ontario M5G 2M9, Canada
  • Local Institution - 0056
    Montreal, Quebec H2X 0A9, Canada
  • Local Institution - 0067
    Marseille, Bouches-du-Rhône 13385, France
  • Local Institution - 0085
    Nantes, 44000, France
  • Local Institution - 0068
    Paris, 75010, France
  • Local Institution - 0102
    Toulouse, 31059, France
  • Local Institution - 0069
    Villejuif, 94800, France
  • Local Institution - 0054
    Tübingen, Baden-Wurttemberg 72076, Germany
  • Local Institution - 0052
    Mainz, Rhineland-Palatinate 55131, Germany
  • Local Institution - 0034
    Berlin, 12200, Germany
  • Local Institution - 0053
    Hamburg, 20251, Germany
  • Local Institution - 0043
    Forlì, 47014, Italy
  • Local Institution - 0042
    Milan, 20132, Italy
  • Local Institution - 0027
    Naples, 80131, Italy
  • Local Institution - 0026
    Rozzano-milano, 20089, Italy
  • Local Institution - 0071
    Krakow, 31-115, Poland
  • Local Institution - 0077
    Warsaw, 02-781, Poland
  • Local Institution - 0045
    Madrid, 28034, Spain
  • Local Institution - 0022
    Madrid, 28040, Spain
  • Local Institution - 0023
    Madrid, 28050, Spain
  • Local Institution - 0044
    Málaga, 29010, Spain
  • Local Institution - 0021
    Pamplona, 31008, Spain
  • Local Institution - 0047
    Santiago de Compostela, 15706, Spain
  • Local Institution - 0049
    Lund, 221 85, Sweden
  • Local Institution - 0040
    Lausanne, 1011, Switzerland
  • Local Institution - 0041
    Sankt Gallen, 9007, Switzerland
  • Local Institution - 0039
    Zurich, 8091, Switzerland
  • Local Institution - 0024
    Manchester, Greater Manchester M20 4BX, United Kingdom
  • Local Institution - 0083
    Glasgow, Lanarkshire G12 0YN, United Kingdom
  • Local Institution - 0019
    Birmingham, West Midlands B15 2TH, United Kingdom
10

References and documents

Publications

  • Cai S, Wei X, Li Q, Jiang Z, Li L. Smart materials in pharmacological drug development: Neutrophils and its constituents for drug delivery and consequent antitumor effects. Mol Immunol. 2025 Jul;183:18-32. doi: 10.1016/j.molimm.2025.04.010. Epub 2025 May 2. PubMed 40318595 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Apr 2024, 74 months.

Results were first posted in Jun 2025, 1 year 1 month after primary completion.

Of 135 industry-sponsored phase 1/2 interventional studies under Melanoma, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 84. This study's 74 months is above that.

Counting every sponsor, half of 220 studies reached it within 60 months; a quarter within 42 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2018
First posted
Jan 17, 2018
StartActual
Feb 12, 2018
Primary completionActual
Apr 26, 2024
CompletionActual
Dec 4, 2025
Results first posted
Jun 19, 2025
Last update
Feb 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT03400332
Responsible party
Sponsor
First posted
Jan 17, 2018
Start date
Feb 12, 2018
Primary completion
Apr 26, 2024
Completion
Dec 4, 2025
Results posted
Jun 19, 2025
Last update
Feb 24, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HuMax-IL8

Start the discussion